市場調查報告書

額顳葉型失智症(FTD):主要7個國家(美國,日本,德國,西班牙,義大利,法國,英國)到2030年前的市場分析,流行病學,市場預測

Frontotemporal Dementia (FTD) - Market Insights, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 938684
出版日期 內容資訊 英文 133 Pages
商品交期: 最快1-2個工作天內
價格
額顳葉型失智症(FTD):主要7個國家(美國,日本,德國,西班牙,義大利,法國,英國)到2030年前的市場分析,流行病學,市場預測 Frontotemporal Dementia (FTD) - Market Insights, Epidemiology and Market Forecast - 2030
出版日期: 2020年05月01日內容資訊: 英文 133 Pages
簡介

主要7個國家(美國,日本,德國,西班牙,義大利,法國,英國)的額顳葉型失智症市場,從2017年到2030年預計將以21.41%的年複合成長率持續成長。

本報告提供主要7個國家的FTD市場調查,提供市場概要,流行病學患者數,各國流行病學,治療和管理,未支援的需求,案例研究,新的治療方法,各國市場分析,促進市場成長的要素及阻礙因素等資訊。

目錄

第1章 主要調查結果

第2章 疾病概要

第3章 SWOT分析

第4章 市場概要

第5章 疾病的背景和概要

  • 簡介
  • FTD的分期與症狀
  • 原因
  • 病理生理學
  • TDP 43蛋白症
  • 病的進展
  • 遺傳學
  • 關聯的額顳葉型失智症症候群
  • 診斷

第6章 流行病學和患者數

  • 主要調查結果
  • 7個國家的整體患病數
  • 7個國家的流行病學的前提條件與根據

第7章 各國流行病學

  • 美國
  • 歐洲5個國家
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第8章 治療和管理

  • 生物標記
  • 病人旅程

第9章 未支援的需求

第10章 案例研究

  • 通過病例報告探索額顳葉癡呆
  • 行為變量FTD表現出冷漠:美國的案例討論

第11章 新治療方法

  • TRx0237:TauRx Therapeutics Ltd
  • AL001:Alector
  • AADvac1:Axon Neuroscience

第12章 其他有潛力的藥劑候補

  • PR006:Prevail Therapeutics
  • Arkuda
  • TDP 43標靶治療:ProMIS Neurosciences
  • ANAVEX 3-71:Anavex

第13章 主要7個國家的市場

  • 主要調查結果
  • 主要7個國家的市場規模

第14章 市場展望:主要7個國家

第15章 各國市場規模

第16章 美國

  • 整體市場規模
  • 各治療法的市場規模

第17章 歐洲5個國家

  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第18章 促進市場成長的要素

第19章 阻礙市場成長要素

第20章 附錄

  • 報告調查手法

章21:DelveInsight的服務內容

第22章 免責聲明

第23章 關於DelveInsight

目錄
Product Code: DIMI0639

DelveInsight's 'Frontotemporal Dementia (FTD) - Market Insights, Epidemiology and Market Forecast-2030' report delivers an in-depth understanding of the disease, historical &forecasted epidemiology as well as the market trends of FTD in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Frontotemporal Dementia (FTD) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2030

Frontotemporal Dementia (FTD) - Disease Understanding and Treatment Algorithm

Frontotemporal Dementia (FTD), is a term used to describe a group of neurocognitive disorders that encompass progressive dysfunction in executive functioning, behavior, and language. It is considered the third most common form of dementia following Alzheimer's disease (AD) and dementia with Lewy bodies. It is a cluster of syndromes that result from degeneration of the frontal and temporal lobes, and is subdivided into two categories that are unique in respect to their predominating presentations; namely, the behavioral subtype that accounts for about half of FTD cases, and the language subtype.

The management of problematic behaviors in FTD with mainly sparse case reports and case series detailing their effectiveness lacks the study quality. Nevertheless, before resorting to pharmacological therapies, nonpharmacological strategies are considered the preferred intervention, which may exacerbate medical comorbidities and thereby affecting more elderly patients. In FTD and related disorders, donepezil, rivastigmine, and galantamine are the three most commonly used acetylcholinesterase. Although none were adequately powered, and only one study was placebo-controlled, results have so far been disappointing across the board.

Frontotemporal Dementia Diagnosis

A 'definite' diagnosis of FTD is still based on neuropathology confirmation postmortem. Improved sensitivity and specificity for bvFTD diagnosis in clinical practice is now possible with the expansion of 'possible' and 'probable' FTD criteria. Patients with bvFTD experience progressive deterioration of behavior and cognition. A recent review of neuroimaging studies has detailed advances in quantifying brain atrophy in FTD using volumetric MRI measurements and by observing hypometabolism in specific regions using [18F] fluorodeoxyglucose PET (18F-FDG PET).

Frontotemporal Dementia Treatment

It covers the details of conventional and current medical therapies available in the Frontotemporal Dementia market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithm across the United States, Europe and Japan.

The DelveInsight Frontotemporal Dementia market report gives a thorough understanding of FTD by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides FTD treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Frontotemporal Dementia Epidemiology

The Frontotemporal Dementia (FTD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. According to DelveInsight, the total number of prevalent cases of Frontotemporal Dementia (FTD) in 7 MM was found to be 76,499 in the year 2017.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Diagnosed Prevalent cases of FTD, Prevalent Cases of FTD by types, Subtype specific cases of Primary Progressive Apahasia and Mutations associated with FTD) scenario of Frontotemporal Dementia (FTD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.

Frontotemporal Dementia Drug Chapters

This segment of the Frontotemporal Dementia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details and the latest news and press releases.

Currently there are no FDA (Food and Drug Administration) or EMA (European Medicines Agency) or PMDA (Pharmaceuticals and Medical Devices Agency) approved disease modifying therapies for the management of FTD. The current treatment strategies mainly rely upon off-label use of medications for symptomatic management, and most therapies lack quality evidence from randomized, placebo-controlled clinical trials. These therapies rely on modulation of neurotransmitter levels and do not target the underlying pathophysiology of FTD. FTD drugs market is categorized on the basis of drug classes such as Selective serotonin reuptake inhibitors (Citalopram, Fluoxetine), Antipsychotic Agents, Cholinesterase Inhibitors (donepezil, rivastigmine and galantamine) NMDA receptor antagonists (Memantine), and Benzodiazepine Antianxiety Drugs.

Frontotemporal Dementia Emerging Drugs

AL001: Alector

AL001 is Alector's wholly owned human monoclonal antibody designed to modulate progranulin, a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including FTD, Alzheimer's disease, and Parkinson's disease. It aims to increase the level of progranulin in humans by inhibiting a progranulin degradation mechanism. In August 2019, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to Alector for the continued development of AL001.

Frontotemporal Dementia Market Outlook

The Frontotemporal Dementia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Frontotemporal Dementia in 7MM is expected to undergo a major positive shift during the course of the study period (2017-2030). The Frontotemporal Dementia market is expected to increase with a CAGR of 21.41% for 7MM during the study period. Among the 7MM, the United States accounts for the largest market size of FTD, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Key Findings

This section includes a glimpse of the Frontotemporal Dementia market in 7MM.

The United States Market Outlook

This section provides the total Frontotemporal Dementia market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Frontotemporal Dementia market size and market size by therapies in Germany, France, Italy, Spain and the United Kingdom is provided in this section.

Japan Market Outlook

The total Frontotemporal Dementia market size and market size by therapies in Japan is also mentioned.

Frontotemporal Dementia Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Frontotemporal Dementia Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Frontotemporal Dementia key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Frontotemporal Dementia emerging therapies.

Reimbursement Scenario in Frontotemporal Dementia

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In report we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business & price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Frontotemporal Dementia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Frontotemporal Dementia market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive & Market Intelligence analysis of the Frontotemporal Dementia Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Frontotemporal Dementia, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
  • Comprehensive insight has been provided into the Frontotemporal Dementia epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Frontotemporal Dementia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Frontotemporal Dementia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Frontotemporal Dementia market

Report Highlights:

  • In the coming years, Frontotemporal Dementia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the Size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Frontotemporal Dementia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Frontotemporal Dementia. Launch of emerging therapies, will significantly impact the Frontotemporal Dementia market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Frontotemporal Dementia
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Frontotemporal Dementia Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Frontotemporal Dementia Report Key Strengths

  • 11 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Frontotemporal Dementia Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Frontotemporal Dementia Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Frontotemporal Dementia total market Size as well as market Size by therapies across the 7MM during the forecast period (2020-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Frontotemporal Dementia Market Size during the forecast period (2020-2030)?
  • At what CAGR, the Frontotemporal Dementia market is expected to grow in 7MM during the study period (2017-2030)?
  • What would be the Frontotemporal Dementia market outlook across the 7MM during the forecast period (2020-2030)?
  • What would be the Frontotemporal Dementia market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Frontotemporal Dementia?
  • What is the historical Frontotemporal Dementia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What would be the forecasted patient pool of Frontotemporal Dementia in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Frontotemporal Dementia?
  • Out of all 7MM countries, which country would have the highest Incident population of Frontotemporal Dementia during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Frontotemporal Dementia along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Frontotemporal Dementia (FTD) in USA, Europe and Japan?
  • What are the Frontotemporal Dementia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy etc.?
  • How many companies are developing therapies for the treatment of Frontotemporal Dementia?
  • How many therapies are developed by each company for the treatment of Frontotemporal Dementia?
  • How many emerging therapies are in mid stage, and late stage of development for the treatment of Frontotemporal Dementia?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Frontotemporal Dementia therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Frontotemporal Dementia and their status?
  • What are the key designations that have been granted for the emerging therapies for Frontotemporal Dementia?
  • What are the global historical and forecasted market of Frontotemporal Dementia?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Frontotemporal Dementia market
  • To understand the future market competition in the Frontotemporal Dementia market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Frontotemporal Dementia in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Frontotemporal Dementia market
  • To understand the future market competition in the Frontotemporal Dementia market

Table of Contents

1. Key Insights

2. Executive Summary of Frontotemporal Dementia

3. SWOT Analysis for Frontotemporal Dementia

4. Frontotemporal Dementia (FTD) Market Overview at a Glance

  • 4.1. Market Share (%) Distribution of Frontotemporal Dementia (FTD) in 2017
  • 4.2. Market Share (%) Distribution of Frontotemporal Dementia (FTD) in 2030

5. Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Stages and Symptoms of FTD
  • 5.3. Causes
  • 5.4. Pathophysiology
  • 5.5. TDP 43 proteinopathy
  • 5.6. Disease progression
  • 5.7. Genetics
  • 5.8. Related Frontotemporal Dementia Syndromes
  • 5.9. Diagnosis

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. 7MM Total Prevalent Patient Population of Frontotemporal Dementia (FTD)
  • 6.3. 7MM - Epidemiology Assumptions and Rationale

7. Country-wise Epidemiology of FTD

  • 7.1. The United States
    • 7.1.1. Diagnosed Prevalent cases of FTD
    • 7.1.2. Prevalent cases of FTD by type
    • 7.1.3. Subtype- specific cases of Primary Progressive Aphasia in the United States
    • 7.1.4. Mutations associated with FTD in the United States
  • 7.2. EU-5
    • 7.2.1. Germany
      • 7.2.1.1. Diagnosed Prevalent cases of FTD
      • 7.2.1.2. Prevalent cases of FTD by type
      • 7.2.1.3. Subtype- specific cases of Primary Progressive Aphasia in Germany
      • 7.2.1.4. Mutations associated with FTD in Germany
    • 7.2.2. France
      • 7.2.2.1. Diagnosed Prevalent cases of FTD
      • 7.2.2.2. Prevalent cases of FTD by type
      • 7.2.2.3. Subtype- specific cases of Primary Progressive Aphasia in France
      • 7.2.2.4. Mutations associated with FTD in France
    • 7.2.3. Italy
      • 7.2.3.1. Diagnosed Prevalent cases of FTD
      • 7.2.3.2. Prevalent cases of FTD by type
      • 7.2.3.3. Subtype- specific cases of Primary Progressive Aphasia in Italy
      • 7.2.3.4. Mutations associated with FTD in Italy
    • 7.2.4. Spain
      • 7.2.4.1. Diagnosed Prevalent cases of FTD
      • 7.2.4.2. Prevalent cases of FTD by type
      • 7.2.4.3. Subtype- specific cases of Primary Progressive Aphasia in Spain
      • 7.2.4.4. Mutations associated with FTD in Spain
    • 7.2.5. The United Kingdom
      • 7.2.5.1. Diagnosed Prevalent cases of FTD
      • 7.2.5.2. Prevalent cases of FTD by type
      • 7.2.5.3. Subtype- specific cases of Primary Progressive Aphasia in The United Kingdom
      • 7.2.5.4. Mutations associated with FTD in The United Kingdom
    • 7.2.6. Japan
      • 7.2.6.1. Diagnosed Prevalent cases of FTD
      • 7.2.6.2. Prevalent cases of FTD by type
      • 7.2.6.3. Subtype- specific cases of Primary Progressive Aphasia in Japan
      • 7.2.6.4. Mutations associated with FTD in Japan

8. Treatment and Management

  • 8.1. Biomarkers for FTD
  • 8.2. Patient Journey

9. Unmet Needs

10. Case Studies

  • 10.1. Exploring frontotemporal dementia through a case report

Title: Exploring frontotemporal dementia through a case report: An emerging public health concern in disguise

  • 10.2. Behavioral variant FTD presenting with apathy: A case Discussion in the US

11. Emerging Therapies

  • 11.1. TRx0237: TauRx Therapeutics Ltd
    • 11.1.1. Product Description
    • 11.1.2. Other Developmental Activities
    • 11.1.3. Clinical Development
      • 11.1.3.1. Clinical trials information
    • 11.1.4. Safety and Efficacy
  • 11.2. AL001: Alector
    • 11.2.1. Product Description
    • 11.2.2. Other Developmental Activities
    • 11.2.3. Clinical Development
      • 11.2.3.1. Clinical trials information
    • 11.2.4. Safety and Efficacy
  • 11.3. AADvac1: Axon Neuroscience
    • 11.3.1. Product Description
    • 11.3.2. Clinical Development
      • 11.3.2.1. Clinical trials information

12. Other Promising Candidates

  • 12.1. PR006: Prevail Therapeutics
    • 12.1.1. Product Description
    • 12.1.2. Other Developmental Activities
  • 12.2. Arkuda
    • 12.2.1. Product Description
  • 12.3. TDP 43 targeting therapeutics: ProMIS Neurosciences
    • 12.3.1. Product Description
  • 12.4. ANAVEX 3-71: Anavex
    • 12.4.1. Product Description
    • 12.4.2. Other Developmental Activities

13. Frontotemporal Dementia (FTD): 7 Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Total Market Size of FTD in 7MM

14. Market Outlook: 7 MM

15. Country-wise Market Size of FTD

16. The United States

  • 16.1. Total Market size of FTD
  • 16.2. FTD Market Size by Therapies

17. EU5 Countries

  • 17.1. Germany
    • 17.1.1. Total Market size of FTD
    • 17.1.2. FTD Market Size by Therapies
  • 17.2. France
    • 17.2.1. Total Market size of FTD
    • 17.2.2. FTD Market Size by Therapies
  • 17.3. Italy
    • 17.3.1. Total Market size of FTD
    • 17.3.2. FTD Market Size by Therapies
  • 17.4. Spain
    • 17.4.1. Total Market size of FTD
    • 17.4.2. FTD Market Size by Therapies
  • 17.5. United Kingdom
    • 17.5.1. Total Market size of FTD
    • 17.5.2. FTD Market Size by Therapies
  • 17.6. Japan
    • 17.6.1. Total Market size of FTD
    • 17.6.2. FTD Market Size by Therapies

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1: Summary of Frontotemporal Dementia (FTD) Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Frontotemporal dementia neuroimaging correlations
  • Table 3: Total Prevalent Patient Population of FTD in 7MM (2017-2030)
  • Table 4: Diagnosed Prevalent Cases of FTD in the United States (2017-2030)
  • Table 5: Prevalent Cases of FTD by type in the United States (2017-2030)
  • Table 6: Subtype- specific cases of Primary Progressive Aphasia in the United States (2017-2030)
  • Table 7: Mutations associated with FTD in the United States (2017-2030)
  • Table 8: Diagnosed Prevalent Cases of FTD in Germany (2017-2030)
  • Table 9: Prevalent Cases of FTD by type in Germany (2017-2030)
  • Table 10: Subtype- specific cases of Primary Progressive Aphasia in Germany (2017-2030)
  • Table 11: Mutations associated with FTD in Germany (2017-2030)
  • Table 12: Diagnosed Prevalent Cases of FTD in France (2017-2030)
  • Table 13: Prevalent Cases of FTD by type in France (2017-2030)
  • Table 14: Subtype- specific cases of Primary Progressive Aphasia in France (2017-2030)
  • Table 15: Mutations associated with FTD in France (2017-2030)
  • Table 16: Diagnosed Prevalent Cases of FTD in Italy (2017-2030)
  • Table 17: Prevalent Cases of FTD by type in Italy (2017-2030)
  • Table 18: Subtype- specific cases of Primary Progressive Aphasia in Italy (2017-2030)
  • Table 19: Mutations associated with FTD in Italy (2017-2030)
  • Table 20: Diagnosed Prevalent Cases of FTD in Spain (2017-2030)
  • Table 21: Prevalent Cases of FTD by type in Spain (2017-2030)
  • Table 22: Subtype- specific cases of Primary Progressive Aphasia in Spain (2017-2030)
  • Table 23: Mutations associated with FTD in Spain (2017-2030)
  • Table 24: Diagnosed Prevalent Cases of FTD in The United Kingdom (2017-2030)
  • Table 25: Prevalent Cases of FTD by type in The United Kingdom (2017-2030)
  • Table 26: Subtype- specific cases of Primary Progressive Aphasia in The United Kingdom (2017-2030)
  • Table 27: Mutations associated with FTD in The United Kingdom (2017-2030)
  • Table 28: Diagnosed Prevalent Cases of FTD in Japan (2017-2030)
  • Table 29: Prevalent Cases of FTD by type in Japan (2017-2030)
  • Table 30: Subtype- specific cases of Primary Progressive Aphasia in Japan (2017-2030)
  • Table 31: Mutations associated with FTD in Japan (2017-2030)
  • Table 32: Diagnostic Markers in Current Use in FTD
  • Table 33: TRx0237, Clinical Trial Description, 2020
  • Table 34: AL001, Clinical Trial Description, 2020
  • Table 35: AADvac1, Clinical Trial Description, 2020
  • Table 36: 7 Major Market Size of FTD in USD Million (2017-2030)
  • Table 37: The US Market size of FTD in USD Million (2017-2030)
  • Table 38: The US market size of FTD by Therapies in USD Million (2017-2030)
  • Table 39: Germany Market size of FTD in USD Million (2017-2030)
  • Table 40: Germany market size of FTD by Therapies in USD Million (2017-2030)
  • Table 41: France Market size of FTD in USD Million (2017-2030)
  • Table 42: France market size of FTD by Therapies in USD Million (2017-2030)
  • Table 43: Italy Market size of FTD in USD Million (2017-2030)
  • Table 44: Italy market size of FTD by Therapies in USD Million (2017-2030)
  • Table 45: Spain Market size of FTD in USD Million (2017-2030)
  • Table 46: Spain market size of FTD by Therapies in USD Million (2017-2030)
  • Table 47: The FTD Market size of FTD in USD Million (2017-2030)
  • Table 48: UK market size of FTD by Therapies in USD Million (2017-2030)
  • Table 49: Japan Market size of FTD in USD Million (2017-2030)
  • Table 50: Japan market size of FTD by Therapies in USD Million (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Types of Frontotemporal Dementia
  • Figure 3: Frontotemporal Dementia spectrum
  • Figure 4: Total Prevalent Patient Population of FTD in 7MM (2017-2030)
  • Figure 5: Diagnosed prevalent cases of FTD in the United States (2017-2030)
  • Figure 6: Prevalent Cases of FTD by type in the United States (2017-2030)
  • Figure 7: Subtype- specific cases of Primary Progressive Aphasia in the United States (2017-2030)
  • Figure 8: Mutations associated with FTD in the United States (2017-2030)
  • Figure 9: Diagnosed prevalent cases of FTD in Germany (2017-2030)
  • Figure 10: Prevalent Cases of FTD by type in Germany (2017-2030)
  • Figure 11: Subtype- specific cases of Primary Progressive Aphasia in Germany (2017-2030)
  • Figure 12: Mutations associated with FTD in Germany (2017-2030)
  • Figure 13: Diagnosed prevalent cases of FTD in France (2017-2030)
  • Figure 14: Prevalent Cases of FTD by type in France (2017-2030)
  • Figure 15: Subtype- specific cases of Primary Progressive Aphasia in France (2017-2030)
  • Figure 16: Mutations associated with FTD in France (2017-2030)
  • Figure 17: Diagnosed prevalent cases of FTD in Italy (2017-2030)
  • Figure 18: Prevalent Cases of FTD by type in Italy (2017-2030)
  • Figure 19: Subtype- specific cases of Primary Progressive Aphasia in Italy (2017-2030)
  • Figure 20: Mutations associated with FTD in Italy (2017-2030)
  • Figure 21: Diagnosed prevalent cases of FTD in Spain (2017-2030)
  • Figure 22: Prevalent Cases of FTD by type in Spain (2017-2030)
  • Figure 23: Subtype- specific cases of Primary Progressive Aphasia in Spain (2017-2030)
  • Figure 24: Mutations associated with FTD in Spain (2017-2030)
  • Figure 25: Diagnosed prevalent cases of FTD in The United Kingdom (2017-2030)
  • Figure 26: Prevalent Cases of FTD by type in The United Kingdom (2017-2030)
  • Figure 27: Subtype- specific cases of Primary Progressive Aphasia in The United Kingdom (2017-2030)
  • Figure 28: Mutations associated with FTD in The United Kingdom (2017-2030)
  • Figure 29: Diagnosed prevalent cases of FTD in Japan (2017-2030)
  • Figure 30: Prevalent Cases of FTD by type in Japan (2017-2030)
  • Figure 31: Subtype- specific cases of Primary Progressive Aphasia in Japan (2017-2030)
  • Figure 32: Mutations associated with FTD in Japan (2017-2030)
  • Figure 33: Unmet needs of FTD
  • Figure 34: 7 Major Market Size of FTD in USD Million (2017-2030)
  • Figure 35: Market Size of FTD in the United States, USD Millions (2017-2030)
  • Figure 36: The U.S. market size of FTD by therapies in USD Million (2017-2030)
  • Figure 37: Market Size of FTD in Germany, USD Millions (2017-2030)
  • Figure 38: Germany market size of FTD by therapies in USD Million (2017-2030)
  • Figure 39: Market Size of FTD in France, USD Millions (2017-2030)
  • Figure 40: France market size of FTD by therapies in USD Million (2017-2030)
  • Figure 41: Market Size of FTD in Italy, USD Millions (2017-2030)
  • Figure 42: Italy market size of FTD by therapies in USD Million (2017-2030)
  • Figure 43: Market Size of FTD in Spain, USD Millions (2017-2030)
  • Figure 44: Spain market size of FTD by therapies in USD Million (2017-2030)
  • Figure 45: Market Size of FTD in the UK, USD Millions (2017-2030)
  • Figure 46: The UK market size of FTD by therapies in USD Million (2017-2030)
  • Figure 47: Market Size of FTD in Japan, USD Millions (2017-2030)
  • Figure 48: Japan market size of FTD by therapies in USD Million (2017-2030)
  • Figure 49: Market drivers for FTD
  • Figure 50: Market barriers for FTD